Dose Adjustments of Tacrolimus Extended Release After Letermovir Initation in Kidney Transplant Recipients (ATC 2026) - Jun 17, 2026 - Abstract #Abstract D317; Pres time: Jun 23, 2026; 02:30 PM - 03:30 PM; Location: Exhibit Hall; "Data for IR TAC suggest 40-60% dose reductions, but the extent of this interaction is less characterized for TAC extended release (TacXR; Envarsus®). Although there was substantial inter-patient variability (SD ±30%), these findings suggest that an empiric 25-30% TacXR dose reduction at LTM initiation may provide a safe and standardized approach for management of this interaction. Unlike the 40% reduction suggested for TacIR, TacXR required a lower reduction of only ~25-30%, supporting formulation-specific dose adjustments to ensure adequate Tac exposure."
Clinical • Infectious Disease • Transplantation • CYP3A5
|
|
K. D. Belfield 1; J. E. Marvin 1; G. Girone 1; R. Formica 2; M. Srinivas 3
|